Microbio received a patent on investigational new drug MB-110 from Intellectual Property Office, Ministry of Economic Affairs, R.O.C. on “PHARMACEUTICAL COMPOSITION FOR HEPATITIS C VIRUS INFECTION THERAPY” on June 1, 2015.

MB-110, a NS5A inhibitor, is developed for the treatment of chronic hepatitis C infection, specifically for patients with genotypes 1b、2a and 3a, which covers the majority of patient populations in China, Korea and Japan. In-vitro cell-based studies have demonstrated its superior efficacy in genotype 1b、2a and 3a with great therapeutic window and synergistic effect when combined with various anti-HCV drugs. The preclinical development work is complete and MB-110 is currently in the preparation for US FDA IND submission to enter Phase I clinical study.